Tumor mutational load predicts survival after immunotherapy across multiple cancer types

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works

Molecular and genetic properties of tumors associated with local immune cytolytic activity

Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · see citing works

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · see citing works

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · see citing works

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · see citing works

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · see citing works

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · see citing works

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503 · see citing works

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119 · see citing works

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635 · see citing works

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408 · see citing works

Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing

Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367 · see citing works

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer

Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191 · see citing works

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · see citing works

Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency

Bouffet, E., Larouche, V., Campbell, B. B., Merico, D., de Borja, R., Aronson, M., Durno, C., Krueger, J., Cabric, V., Ramaswamy, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.6552 · Cited by 857 · see citing works

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1337 · Cited by 643 · see citing works

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481 · see citing works

Targeting T Cell Co-receptors for Cancer Therapy

Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.023 · Cited by 468 · see citing works

Neoantigen landscape dynamics during human melanoma–T cell interactions

Verdegaal, E. M. E., de Miranda, N. F. C. C., Visser, M., Harryvan, T. J., van Buuren, M. M., Andersen, R. S., Hadrup, S. R., van der Minne, C. E., Schotte, R., Spits, H., et al. (2016) · Nature · doi:10.1038/nature18945 · Cited by 464 · see citing works

Epitope Landscape in Breast and Colorectal Cancer

Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416 · see citing works

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

Janjigian, Y. Y., Sánchez-Vega, F., Jonsson, P., Chatila, W. K., Hechtman, J. F., Ku, G. Y., Riches, J. C., Tuvy, Y., Kundra, R., Bouvier, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0787 · Cited by 374 · see citing works

Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set

Roszik, J., Haydu, L. E., Hess, K. R., Oba, J., Joon, A. Y., Siroy, A. E., Karpinets, T. V., Stingo, F. C., Baladandayuthapani, V., Tetzlaff, M. T., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0705-4 · Cited by 115 · see citing works

Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

Cohen, E. E. W., Harrington, K. J., Tourneau, C. L., Dinis, J., Licitra, L. F., Ahn, M.-J., Soria, A., Machiels, J.-P., Mach, N., Mehra, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx440.040 · Cited by 91 · see citing works

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

Cohen, E. E. W., Licitra, L. F., Burtness, B. A., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx344 · Cited by 80 · see citing works

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer

Bendell, J. C., Ciardiello, F., Tabernero, J. M., Tebbutt, N. C., Eng, C., Bartolomeo, M. D., Falcone, A., Fakih, M., Kozloff, M. F., Segal, N. H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy208.003 · Cited by 50 · see citing works

Assessment of tumor mutation burden from >60,000 clinical cancer patients using comprehensive genomic profiling.

Frampton, G. M., Fabrizio, D. A., Chalmers, Z. R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.11558 · Cited by 8 · see citing works

A phase I trial of vorolanib (X-82t vascular endothelial growth factor receptor (VEGFR) inhibitor, in patients (pts) with advanced solid tumors

Bendell, J. C., Moore, K. N., Patel, M. R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy303.032 · Cited by 2 · see citing works

Nivolumab plus ipilimumab in advanced non-small-cell lung cancer

Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823 · see citing works

Top 10 Challenges in Cancer Immunotherapy

Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238 · see citing works

Immunotherapy in colorectal cancer: Rationale, challenges and potential

Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954 · see citing works

Tertiary lymphoid structures in the era of cancer immunotherapy

Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884 · see citing works

Immunotherapies for hepatocellular carcinoma

Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843 · see citing works

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586 · see citing works

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192 · see citing works

Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma

Gao, Q., Zhu, H., Dong, L., Shi, W., Chen, R., Song, Z., Huang, C., Li, J., Dong, X., Zhou, Y., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.052 · Cited by 1,096 · see citing works

Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition

Litchfield, K., Reading, J. L., Puttick, C., Thakkar, K., Abbosh, C., Bentham, R., Watkins, T. B. K., Rosenthal, R., Biswas, D., Rowan, A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.002 · Cited by 893 · see citing works

Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors

Sha, D., Jin, Z., Budczies, J., Kluck, K., Stenzinger, A., & Sinicrope, F. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0522 · Cited by 859 · see citing works

Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer

Rolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., Bivona, T., Diehn, M., Dive, C., Dziadziuszko, R., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.017 · Cited by 683 · see citing works

Harnessing multimodal data integration to advance precision oncology

Boehm, K. M., Khosravi, P., Vanguri, R., Gao, J., & Shah, S. P. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00408-3 · Cited by 662 · see citing works

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

Rizvi, N. A., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M.-J., van den Heuvel, M. M., Cobo, M., Vicente, D., Smolin, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0237 · Cited by 623 · see citing works

Turning cold tumors hot: from molecular mechanisms to clinical applications

Zhang, J., Huang, D., Saw, P. E., & Song, E. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.010 · Cited by 534 · see citing works

Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction

Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.015 · Cited by 538 · see citing works

Proteogenomic Characterization of Endometrial Carcinoma

Dou, Y., Kawaler, E. A., Cui Zhou, D., Gritsenko, M. A., Huang, C., Blumenberg, L., Karpova, A., Petyuk, V. A., Savage, S. R., Satpathy, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.026 · Cited by 485 · see citing works

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors

Valero, C., Lee, M., Hoen, D., Weiss, K., Kelly, D. W., Adusumilli, P. S., Paik, P. K., Plitas, G., Ladanyi, M., Postow, M. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-20935-9 · Cited by 441 · see citing works

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma

McBride, S., Sherman, E., Tsai, C. J., Baxi, S., Aghalar, J., Eng, J., Zhi, W. I., McFarland, D., Michel, L. S., Young, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.00290 · Cited by 402 · see citing works

Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy

Jiao, S., Subudhi, S. K., Aparicio, A., Ge, Z., Guan, B., Miura, Y., & Sharma, P. (2019) · Cell · doi:10.1016/j.cell.2019.10.029 · Cited by 386 · see citing works

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391 · see citing works

The molecular biology of pancreatic adenocarcinoma: Translational challenges and clinical perspectives

Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00659-4 · Cited by 369 · see citing works

Exploring immunotherapy in colorectal cancer

Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355 · see citing works

Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma

Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356 · see citing works

Understanding the tumor microenvironment for effective immunotherapy

Sadeghi Rad, H., Monkman, J., Warkiani, M. E., Ladwa, R., O'Byrne, K., Rezaei, N., & Kulasinghe, A. (2021) · Medicinal Research Reviews · doi:10.1002/med.21765 · Cited by 334 · see citing works

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer

Hammerl, D., Martens, J. W. M., Timmermans, M., Smid, M., Trapman-Jansen, A. M., Foekens, R., Isaeva, O. I., Voorwerk, L., Balcioglu, H. E., Wijers, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25962-0 · Cited by 262 · see citing works

A Vision-Language Foundation Model for Precision Oncology

Xiang, J., Wang, X., Zhang, X., Xi, Y., Eweje, F., Chen, Y., Li, Y., Bergstrom, C., Gopaulchan, M., Kim, T., et al. (2025) · Nature · doi:10.1038/s41586-024-08378-w · Cited by 256 · see citing works

Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

Nacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30453-x · Cited by 232 · see citing works

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients

Wang, Y., Tong, Z., Zhang, W., Zhang, W., Buzdin, A., Mu, X., Yan, Q., Zhao, X., Chang, H.-H., Duhon, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.683419 · Cited by 224 · see citing works

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Samstein, R. M., Krishna, C., Ma, X., Pei, X., Lee, K.-W., Makarov, V., Kuo, F., Chung, J., Srivastava, R. M., Purohit, T. A., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00139-8 · Cited by 219 · see citing works

Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma

Limeta, A., Ji, B., Levin, M., Gatto, F., & Nielsen, J. (2020) · JCI Insight · doi:10.1172/jci.insight.140940 · Cited by 185 · see citing works

Technological advances in cancer immunity: from immunogenomics to single‐cell analysis and artificial intelligence

Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163 · see citing works

CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer

Lin, A., Qi, C., Wei, T., Li, M., Cheng, Q., Liu, Z., Luo, P., & Zhang, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac129 · Cited by 152 · see citing works

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G₄ Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00210 · Cited by 175 · see citing works

Genomic instability, inflammatory signaling and response to cancer immunotherapy

Chen, M., Linstra, R., & van Vugt, M. A. T. M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188661 · Cited by 166 · see citing works

Targeting the interleukin-17 immune axis for cancer immunotherapy

Vitiello, G. A., & Miller, G. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190456 · Cited by 151 · see citing works

Alveolar Differentiation Drives Resistance to <i>KRAS</i> Inhibition in Lung Adenocarcinoma

Li, Z., Zhuang, X., Pan, C.-H., Yan, Y., Thummalapalli, R., Hallin, J., Torborg, S., Singhal, A., Chang, J. C., Manchado, E., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0289 · Cited by 74 · see citing works

Distinct PD-L1/PD1 profiles and clinical implications in intrahepatic cholangiocarcinoma patients with different risk factors

Lu, J.-C., Zeng, H.-Y., Sun, Q.-M., Meng, Q.-N., Huang, X.-Y., Zhang, P.-F., Yang, X., Peng, R., Gao, C., Wei, C.-Y., et al. (2019) · Theranostics · doi:10.7150/thno.36276 · Cited by 72 · see citing works

Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4

van den Bulk, J., Verdegaal, E. M. E., Ruano, D., Ijsselsteijn, M. E., Visser, M., van der Breggen, R., Duhen, T., van der Ploeg, M., de Vries, N. L., Oosting, J., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0697-8 · Cited by 63 · see citing works

KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma

Frost, N., Kollmeier, J., Vollbrecht, C., Grah, C., Matthes, B., Pultermann, D., von Laffert, M., Lüders, H., Olive, E., Raspe, M., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-958 · Cited by 61 · see citing works

ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment

Yi, R., Lin, A., Cao, M., Xu, A., Luo, P., & Zhang, J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00933 · Cited by 60 · see citing works

Biomarkers for Response to Immune Checkpoint Blockade

Ganesan, S., & Mehnert, J. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033604 · Cited by 51 · see citing works

Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response

Kim, C. G., Koh, J.-Y., Shin, S.-J., Shin, J.-H., Hong, M., Chung, H. C., Rha, S. Y., Kim, H. S., Lee, C.-K., Lee, J. H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101251 · Cited by 45 · see citing works

Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy

Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40 · see citing works

MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer

Yi, R., Hong, S., Zhang, Y., Lin, A., Ying, H., Zou, W., Wang, Q., Wei, T., Cheng, Q., Zhu, W., et al. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.757137 · Cited by 37 · see citing works

Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma

Jammihal, T., Saliby, R. M., Labaki, C., Soulati, H., Gallegos, J., Peris, A., McCurry, D., Yu, C., Shah, V., Poduval, D., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00896-w · Cited by 38 · see citing works

Deep learning in digital pathology for personalized treatment plans of cancer patients

Wen, Z., Wang, S., Yang, D. M., Xie, Y., Chen, M., Bishop, J., & Xiao, G. (2023) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2023.02.003 · Cited by 34 · see citing works

Comprehensive analysis of DNA damage repair deficiency in 10,284 pan–cancer study

Xiao, Y., Lu, D., Lei, M., Xie, W., Chen, Y., Zheng, Y., Wang, C., Zhao, J., Zhu, Z., Zhao, X., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-5449 · Cited by 22 · see citing works

High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: Diverse molecular associations point to variable pathophysiology

Voutsadakis, I. A. (2023) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2023.100746 · Cited by 14 · see citing works

T cell proliferation-related genes: predicting prognosis, identifying the cold and hot tumors, and guiding treatment in clear cell renal cell carcinoma

Huang, H., Cai, Y., Hong, X., Gao, W., Tang, J., Zhang, S., & Xu, Z. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.948734 · Cited by 6 · see citing works

Immunotherapeutic strategies in breast cancer: a clinical update

Zhang, J. Q., & Plitas, G. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26287 · Cited by 6 · see citing works

Prognostic significance and immune characteristics of GPR27 in gastric cancer

Pan, J., & Gao, Y. (2023) · Aging · doi:10.18632/aging.205023 · Cited by 6 · see citing works

Is Treatment Response Prognostic in Non–Small-Cell Lung Cancer?

Tsao, A. S. (2015) · Journal watch · doi:10.1056/nejm-jw.na37418

Cetuximab combined with chemotherapy prolonged the overall survival of advanced NSCLC

Cheng, G. (2008) · doi:10.3760/cma.j.issn.1006-9801.2008.08.001

Physicians prognosis of survival in non small cell lung cancer (NSCLC): comparison with prognostic factors

(1991) · Lung Cancer · doi:10.1016/0169-5002(91)92023-c

Quality of life (QL) is a prognostic factor (PF) for survival in patients with advanced colorectal cancer (CRC)

Hilgenfeld, R. U., Mansmann, U., Guggenmoos-Holzmann, I., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)85390-7 · Cited by 5 · see citing works

Docetaxel for 15 patients with paclitaxel-resistant advanced non-small cell lung cancer

Zhang, Y., Xu, Y., Ye, X., et al. (2009) · doi:10.3760/cma.j.issn.1006-9801.2009.07.009